Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Staar Surgical ( (STAA) ).
On August 4, 2025, STAAR Surgical Company entered into a merger agreement with Alcon, where STAAR will become a wholly owned subsidiary of Alcon. The merger, valued at approximately $1.5 billion, involves Alcon purchasing all outstanding shares of STAAR for $28 per share, representing a significant premium over STAAR’s recent stock prices. The acquisition is expected to complement Alcon’s laser vision correction business and be accretive in the second year. The transaction is anticipated to close within six to twelve months, subject to customary conditions and regulatory approvals.
The most recent analyst rating on (STAA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The overall stock score reflects significant financial challenges, particularly in profitability and cash flow, despite a strong balance sheet. Technical indicators show moderate positive momentum, while corporate events and strategic initiatives provide some optimism. Valuation remains a concern due to negative earnings.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical is a leader in refractive surgery, specializing in Implantable Collamer Lenses (ICL) for vision correction, particularly for patients with moderate to high myopia, with or without astigmatism.
Average Trading Volume: 811,834
Technical Sentiment Signal: Sell
Current Market Cap: $879.6M
For an in-depth examination of STAA stock, go to TipRanks’ Overview page.